Immuno Aktiengesellschaft

Baxter Aktiengesellschaft

Immuno Aktiengesellschaft Fur Chemisch-medizinische Produkte

Martha Eibl

Heinz Leibl

Hermann Wolf

Yendra Linnau

Regine Tomasits

Josef W Mannhalter

Otto Schwarz

Josef Mannhalter

A method for the separation of IgG and IgA from an immunoglobulin-containing starting material is described, whereby the method is characterized in that (i) IgG and optionally IgA are adsorbed to a solid inorganic carrier material, (ii) IgA is isolated from the eluate, optionally after selective desorption, whereas IgG remains on the carrier material, and optionally (iii) IgG is isolated from the adsorbate. Furthermore, an IgA preparation is disclosed which demonstrates a low tendency to form aggregates.

Process for isolating IgG and IgA

Inflammation can be treated or prevented altogether by administering a preparation comprising IgA. These preparations also can effect immunomodulation. Preferably, the preparation includes multimeric IgA and is essentially free of IgG in its various forms. Other compounds, such as antibiotics, antiphlogistic agents and antacids, also may be administered. Immunoglobulin A may also be used in vaccines to prevent inflammation. Additionally, an improved assay for evaluating anti-inflammatory activity is provided.

Composition and method for preventing and treating inflammation with

A virus-safe monomeric human IgA is described which is essentially free of IgG. The IgA according to the invention is obtainable according to a process in which (a) an IgA-containing fraction is subjected to a purification such that a monomeric IgA which is essentially free of IgG is obtained and (b) the obtained product is subjected to a process for the inactivation of viruses.

Virus-safe monomeric human immunoglobulin A and methods for its

A method of preparing an intravenously administrable immune globulin preparation containing antibodies, in which human blood plasma is fractionated and an immune-globulin-containing fraction is freed from undesired protein impurities by a single or repeated precipitation with polyethylene glycol, is characterized in that the immune-globulin-containing fraction is subjected in a first purification step prior to the polyethylene glycol precipitation to a treatment with an aqueous solution of a salt of an inorganic acid, and in that at least one of the following purification steps is carried out with polyethylene glycol in the presence of a soluble carbohydrate or a non-protein-precipitating polyol, whereupon the immune globulin freed from protein impurities is precipitated from the remaining solution by water-soluble polymers and is finished in a known manner to the pharmaceutical preparation.

Growing community of inventors

Vienna, Austria

Martha Eibl